

## **Oncobiologics Announces Pricing of Its Initial Public Offering of Units**

May 12, 2016 6:16 PM ET

CRANBURY, N.J., May 12, 2016 /PRNewswire/ -- Oncobiologics, Inc. (NASDAQ: ONSIU), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, today announced the pricing of its initial public offering of 5,833,334 units at a price to the public of \$6.00 per unit. Each unit consists of one share of common stock, one-half of a Series A warrant and one-half of a Series B warrant. Each whole Series A warrant entitles the holder to purchase one share of Oncobiologics' common stock at an initial exercise price of \$6.60, subject to adjustment. Each whole Series B warrant entitles the holder to purchase one share of Oncobiologics' common stock at an initial exercise price of \$8.50, subject to adjustment. Oncobiologics, Inc. also has granted the underwriters a 30-day option to purchase up to an additional 875,000 units at the initial public offering price per unit to cover over-allotments, if any. All of the units are being offered by Oncobiologics, Inc. Concurrently with the offering, Oncobiologics, Inc. is also selling, through a separate private placement, 833,332 units to Sabby Healthcare Master Fund Ltd., an existing stockholder, at the initial public offering price per unit.

The units are expected to begin trading on the NASDAQ Global Market on May 13, 2016 under the ticker symbol "ONSIU." The common stock, Series A warrants and Series B warrants comprising the units will begin trading separately on the NASDAQ Global Market under the symbols "ONS," "ONSIW" and "ONSIZ," respectively, on the first trading day following the expiration of the underwriters' 30-day over-allotment option, at which time trading of the units will be suspended and the units will be delisted.

The closing of the offering is expected to occur on May 18, 2016, subject to the satisfaction of customary closing conditions.

Jefferies LLC and Barclays Capital Inc. are serving as joint book-running managers for the offering. Cantor Fitzgerald is acting as co-manager.

The offering is being made solely by means of a prospectus, a copy of which may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, email: [Prospectus\\_Department@Jefferies.com](mailto:Prospectus_Department@Jefferies.com) or from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (888) 603-5847, e-mail: [Barclaysprospectus@broadridge.com](mailto:Barclaysprospectus@broadridge.com).

A registration statement relating to these securities has been filed with the SEC and became effective on May 12, 2016. This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

### **About Oncobiologics, Inc. and its BioSymphony™ Platform**

Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Its current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. Oncobiologics is advancing its pipeline of eight biosimilar products, two of which are currently in clinical development. Led by a team of biopharmaceutical experts, Oncobiologics operates from in-house state-of-the-art fully integrated research and development, and manufacturing facility in Cranbury, New Jersey. Oncobiologics employs its BioSymphony™ Platform to address the challenges of biosimilar development and commercialization by developing high quality mAb biosimilars in an efficient and cost-effective manner on an accelerated timeline.

### **CONTACTS:**

#### **Oncobiologics:**

Lawrence A. Kenyon  
Chief Financial Officer  
[LawrenceKenyon@oncobiologics.com](mailto:LawrenceKenyon@oncobiologics.com)

**Media:**

Alex Fudukidis  
Russo Partners, LLC  
[alex.fudukidis@russopartnersllc.com](mailto:alex.fudukidis@russopartnersllc.com)

**Investors:**

Robert Flamm, Ph.D.  
Russo Partners, LLC  
[robert.flamm@russopartnersllc.com](mailto:robert.flamm@russopartnersllc.com)

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/oncobiologics-announces-pricing-of-its-initial-public-offering-of-units-300268062.html>

SOURCE Oncobiologics, Inc.